LBBAL™ Alianza is a boutique strategic consulting firm specializing in M&A, due diligence, technology transfers, alliance management, and dispute resolution in biotechnology, pharmaceutical, and diagnostics sectors.
We combine international experience in big pharma and biotech with a practical, results-driven approach, helping companies and professionals transform complex processes into solid deals and partnerships with high global impact.
I founded LBBAL™ Alianza after recognizing that many organizations require alliance and M&A experts quickly and temporarily, especially during critical due diligences, post-merger integrations, or complex disputes. Our goal is to support and complement internal teams, providing expertise, efficiency, and security in every operation.
To drive client success by providing due diligence, negotiation and integration support,managing technology transfers and alliances, and providing dispute resolution support in an efficient and reliable manner, reducing risks and maximizing growth opportunities.
To establish ourselves as a top tier boutique consulting firm operating globally in M&A, due diligence, technology transfers, alliance management, and dispute resolution in biotechnology, diagnostics, and pharma, recognized for making the complex simple and helping our clients realize the benefits envisioned in their negotiations.
Credibility and real experience: international track record in big pharma and biotech.
Speed and pragmatism: clear and efficient approach solutions.
Trust and ethics: relationships based on transparency and accuracy.
International vision: global approach with local sensibility.
Tangible results: partnerships that generate growth and consistency.
Real experience in international big pharma and biotech
Agility and efficiency: we identify the essentials and deliver quickly without compromising accuracy.
Credibility and trust: providing confidence to CEOs, corporate directors, lawyers, and investors.
Ability to simplify: so our clients can focus on their priorities, without wasting time or missing opportunities.
Results: stronger partnerships, faster execution, mitigatedrisks, and realized deal value.
Fundadora y directora ejecutiva de LBBAL™ Alianza, S.L.
Prior to launching LBBAL™ Alianza, Dr. Rosoff was a partnering executive with roles of increasing seniority at Genentech, Gilead, Kite and Exelixis. Over the course of over two decades, she had the opportunity to lead and participate in a wide diversity of deals, negotiations, diligence exercises, alliances, technology transfers, M&A integrations, dispute resolution negotiations, amendments and terminations–at all stages of the drug development and commercialization lifecycle and in multiple therapeutic areas.
Dr. Rosoff earned a doctorate in Pharmacology from the University of Washington, where she was an HHMI pre-doctoral fellow in the laboratory of Randall T. Moon. She conducted her postdoctoral work at Stanford, studying Wnt signal transduction and cell adhesion under the guidance of James Nelson. Dr. Rosoff additionally gained valuable applied biotechnology experience at Ingenuity Systems (now part of Qiagen), Caliper Life Sciences and Lynx Therapeutics (now part of Illumina) in operational, program management and business development roles.
Expert in due diligence, asset transfer, tech transfer, alliance management and database/AI implementation.
Holds a PhD in Chemical Biology and performed research in academia (Scripps and UCSF) and industry focusing on protein glycosylation and the design of protein-drug conjugates and bi-specific molecules targeting T-cell engagement. Desiree worked at Amunix and Nura as a Senior Scientist responsible for research programs, IND package generation and CRO management. She then transitioned to the management of partnerships at Atomwise, Exelixis and SandboxAQ. In these roles, Desiree has managed partnerships where artificial intelligence is a key contributor to the collaboration workflow, and has gained substantial expertise in asset divestiture, asset integration and technology transfer.
With LBBALTM Alianza, Desiree is available to deliver consulting services related to deal diligence, database implementation, meeting facilitation and documentation, contractual obligation and milestone tracking, joint budget management, and custom technology transfer, asset transfer and M&A integration assignments.
Expert in R&D strategy, investment pitch and deal diligence, and research/clinical development plans.
Is a seasoned biologist with 15 years of experience in research and therapeutics. Trained at renowned institutions like the Salk Institute, UCSD, and the European Institute of Oncology, Gabriele has a strong publication record in high-impact journals such as Nature, Nature Cell Biology, and Nature Reviews Cancer.
Gabriele led drug discovery programs from early-stage research to IND applications and in addition provided strategic input across to research, commercial planning, and business development. Gabriele is available to advise LBBALTM Alianza’s clients regarding deal pitch decks, deal diligence, collaborative R&D work plans designed to achieve critical milestones (e.g., target selection, experimental design, success criteria definition, biomarker identification), clinical plans and CRO and KOL selection.
Expert in preclinical and clinical biological assays, experimental design, scientific due diligence and data and experimental methods transfer.
Ford H-Kirschenbaum, Ph.D. possesses thirty years of drug development experience with significant breadth of expertise in driving bespoke assay development/optimizations in diverse therapeutic areas while at Scios/J&J, Roche, Nuvelo, Gilead, AMT, Tizona and Moonwalk. This includes target ID, small molecule/large molecule hit-to-lead ID, potency/IC50, hit-to-lead, HTS, MoA, cytotoxicity, antibody discovery, T cell functional assays, tissue and serum/blood/PBMC biomarker assay development/validation for PK/PD, (MSD ELISA and IHC/ISH), as well as deep molecular biology (RNA, NGS, CRISPR), cell culture and cell transduction knowledge.
Representing LBBALTM Alianza, Ford can provide clients with a best-in-class assessment of the quality and viability of R&D plans and identify risks and opportunities during deal diligence. Ford is also available to support clients on a fractional basis with technology transfers, asset purchases and technically focused M&A integration activities
Expert in statistical methodology, clinical study design and decision support, including presenting before regulatory agencies.
Has more than 30 years’ experience in statistical methodology, management and clinical biostatistics applied to clinical research and drug development, with stints at Janssen/J&J, Actelion, Novartis, Merck-Serono and Serono. Marisa is passionate about providing quantitative support to strategic decision making and has supported drug development for rare and complex diseases in oncology, neurosciences, immunology and PAH. Marisa is the former president of the European Federation of Statisticians in the Pharma Industry (EFSPI) and a current member of the Basler Biometric Society Council.
Marisa is available as an expert arbitration and litigation witness and as an advisor to executive LBBALTM Alianza clients providing quantitative decision making support regarding critical questions relating to study and program design, challenges and opportunities including interactions with regulators, evidence generation, use of RWE, use of digital endpoints & PROs, among others. Additionally, Marisa is available to provide expert consulting services in the areas of due diligence, term sheet & contract review, facilitation of joint data monitoring committees, and custom fractional assignments related to M&A organizational integrations of analytical/biometric functions.
Expert in portfolio and program management, operational excellence and cross functional alignment, driving execution in alliance management, tech transfer and integrations.
Is a global biotechnology executive with more than 25 years of experience advancing programs from early research to commercialization across oncology, autoimmune, and metabolic diseases. He has held senior leadership roles at argenx, Caribou Biosciences, Nestlé Health Science, Roche, and Gilead, where he built and managed multi-billion-dollar portfolios and guided multiple IND approvals. He brings a disciplined approach to portfolio and program management, integrating scientific, clinical, and business priorities to accelerate development and optimize resource allocation. Known for transparent governance and executive alignment, Saeid works across organizations to ensure strategic focus, operational efficiency, and measurable outcomes. Saeid is available to provide due diligence, integration, tech transfer, alliance management and dispute resolution services.
LBBAL Biotech M&A Associate for due diligence & M&A support.
Holds an MBA from IMD, an MRes in Biomedical Research from St George’s, and a BSc in Biology from Loyola University Chicago. His experience spans laboratory R&D, clinical quality assurance, product marketing, and venture support. Prior roles include Investor Relations at Bio.Incubate in Zurich, Research Analyst at Venture Valuation, GCP QA consultant at Azizi Pharmaceutical Services, marketing at Miltenyi Biotec, and R&D at PerkinElmer/BioLegend.
Shawheen’s focus at LBBAL™ Alianza includes building investor and buyer lists, developing financial models and pitch materials, validating value propositions with market input, and coordinating cross-border outreach. He has designed diligence templates, assembled global VC targets, and supported negotiations by aligning technical, regulatory, and commercial narratives.
Expert in Alliance Management and Corporate Strategy
Krishna has 30 years of business and scientific experience in the biotechnology and pharmaceutical sectors. He brings deep expertise in alliance management, program leadership, corporate strategy and development, and pharmaceutical R&D. Most recently, at Gilead Sciences and Alector Therapeutics, Krishna led more than twenty-five complex strategic deals across oncology, inflammation, virology, and neuroscience—spanning preclinical discovery, early- and late-stage clinical development, and commercial phases.
Krishna has hands-on experience overseeing joint R&D collaborations, co-commercialization alliances, licensing and option agreements, staged acquisitions, and divestitures. Previously, he was a management consultant at Accenture, where he developed growth strategies for Fortune 500 pharmaceutical and medical device companies. Earlier in his career as a medicinal chemist, Krishna led scientific R&D programs in oncology, antifungal, and antibacterial therapeutics at GPC Biotech and Mitotix.
Krishna holds a PhD in Organic Chemistry from Case Western Reserve University and an MBA from the MIT Sloan School of Management. He is available to provide due diligence and M&A services.
